Truist Securities Maintains Buy on Chemours, Lowers Price Target to $20
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $24 to $20.
Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $24 to $20.